Cargando…
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro tra...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879815/ https://www.ncbi.nlm.nih.gov/pubmed/29609658 http://dx.doi.org/10.1186/s40360-018-0204-7 |
_version_ | 1783311056325574656 |
---|---|
author | Kyung, Sun Young Kim, Dae Young Yoon, Jin Young Son, Eun Suk Kim, Yu Jin Park, Jeong Woong Jeong, Sung Hwan |
author_facet | Kyung, Sun Young Kim, Dae Young Yoon, Jin Young Son, Eun Suk Kim, Yu Jin Park, Jeong Woong Jeong, Sung Hwan |
author_sort | Kyung, Sun Young |
collection | PubMed |
description | BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. METHODS: In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. RESULTS: SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. CONCLUSIONS: SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-018-0204-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5879815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58798152018-04-04 Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition Kyung, Sun Young Kim, Dae Young Yoon, Jin Young Son, Eun Suk Kim, Yu Jin Park, Jeong Woong Jeong, Sung Hwan BMC Pharmacol Toxicol Research Article BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. METHODS: In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. RESULTS: SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. CONCLUSIONS: SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-018-0204-7) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-02 /pmc/articles/PMC5879815/ /pubmed/29609658 http://dx.doi.org/10.1186/s40360-018-0204-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kyung, Sun Young Kim, Dae Young Yoon, Jin Young Son, Eun Suk Kim, Yu Jin Park, Jeong Woong Jeong, Sung Hwan Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title | Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title_full | Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title_fullStr | Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title_full_unstemmed | Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title_short | Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
title_sort | sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879815/ https://www.ncbi.nlm.nih.gov/pubmed/29609658 http://dx.doi.org/10.1186/s40360-018-0204-7 |
work_keys_str_mv | AT kyungsunyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT kimdaeyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT yoonjinyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT soneunsuk sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT kimyujin sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT parkjeongwoong sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition AT jeongsunghwan sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition |